As of August 2026, no distinct new U.S. treatment specifically for back acne had been verified; denifanstat had only cleared the FDA step needed to begin Phase 3 testing.
Established treatments therefore still guide care, while patients should watch the denifanstat trial and delayed iPLEDGE changes—not assume a new drug is available. Back acne is often called truncal acne, a term covering acne on the back and chest. The practical update involves an investigational oral drug, clearer antibiotic limits, an isotretinoin program delay, and perspective on benzoyl peroxide recalls.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed with denifanstat?
- Which back-acne treatments still have evidence?
- How long should oral antibiotics be used?
- What does the iPLEDGE delay mean?
- Should benzoyl peroxide users be concerned about recalls?
What changed with denifanstat?
Sagimet Biosciences reported FDA clearance to begin a Phase 3 trial of denifanstat, an investigational oral acne drug. This clearance allows the study to proceed; it is not FDA approval to prescribe or market the drug. The planned trial will enroll about 800 U.S.
patients aged 12 or older with moderate-to-severe acne. Participants will receive daily denifanstat or placebo for 12 weeks, according to Sagimet's August 2026 announcement. Until that trial produces results, denifanstat cannot be considered effective for back acne or ready for routine use. The important questions are whether it improves truncal acne, how its safety compares with existing options, and whether benefits persist beyond 12 weeks.
Which back-acne treatments still have evidence?
The American Academy of Dermatology strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and combination topical treatment for acne. It advises using antibiotics with benzoyl peroxide and limiting oral-antibiotic exposure. Trifarotene has direct trial evidence for truncal acne.
In the FDA's pivotal review, once-daily 0.005% cream produced clear-or-almost-clear trunks in 35.7% versus 25.0% of participants in one trial and 42.6% versus 29.9% in another at 12 weeks. Those results represent advantages of 10.7 and 12.7 percentage points over the vehicle cream, not guaranteed clearing for every patient according to the FDA review. Evidence remains insufficient for the AAD to recommend chemical peels, lasers or light devices, microneedling, dietary changes, vitamins, or plant-based treatments. New attention around these approaches does not mean they have replaced established back-acne care.
How long should oral antibiotics be used?
The 2025 EuroGuiDerm update advises limiting systemic antibiotics for acne to three months because of antibiotic-resistance concerns. It allows longer treatment to be considered when truncal acne has only partly improved and other options are unsuitable.
That exception is not a reason to continue antibiotics indefinitely. A useful medication review should address: Patients should not stop a prescribed antibiotic without discussing the plan with their prescriber. The guideline supports an individualized decision, but resistance risk remains part of that decision.
- Whether the back acne has clearly improved
- Whether benzoyl peroxide is part of the antibiotic plan
- Whether a non-antibiotic maintenance treatment can take over
- Why an extension is preferable to another suitable option
What does the iPLEDGE delay mean?
FDA postponed planned iPLEDGE changes for isotretinoin from August 8 to November 15, 2026. Patients and prescribers should expect existing pregnancy-testing procedures to remain in effect until then, despite planned changes intended to reduce administrative burden under the FDA's revised timeline.
Anyone starting or continuing isotretinoin during this period should confirm current requirements with the prescribing office before each deadline. Assuming the August changes already apply could interrupt access even when the treatment plan itself has not changed.
Should benzoyl peroxide users be concerned about recalls?
FDA testing found elevated benzene in six of 95 benzoyl peroxide acne products and prompted voluntary retail-level recalls. More than 90% of tested products had undetectable or extremely low benzene levels, and the agency characterized the cancer risk from recalled products as very low in its March 2025 notice.
This finding does not support treating every benzoyl peroxide product as unsafe. Check the exact product against the FDA recall information; if it matches, follow the retailer's or manufacturer's return or disposal directions.